KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLoans and Notes ReceivablesLong-Term Debt IssuancesNon-Current ReceivablesReceivables RefundsShares Repurchased
Ratios

Royalty Pharma (RPRX) EBIAT (2019 - 2025)

Royalty Pharma's EBIAT history spans 7 years, with the latest figure at $214.2 million for Q4 2025.

  • For Q4 2025, EBIAT fell 68.5% year-over-year to $214.2 million; the TTM value through Dec 2025 reached $770.9 million, down 45.48%, while the annual FY2025 figure was $770.9 million, 42.07% down from the prior year.
  • EBIAT for Q4 2025 was $214.2 million at Royalty Pharma, down from $288.2 million in the prior quarter.
  • Across five years, EBIAT topped out at $1.1 billion in Q4 2023 and bottomed at -$610.0 million in Q4 2022.
  • The 5-year median for EBIAT is $217.3 million (2022), against an average of $258.5 million.
  • The largest annual shift saw EBIAT crashed 7817.99% in 2022 before it surged 5678.02% in 2025.
  • A 5-year view of EBIAT shows it stood at $7.9 million in 2021, then plummeted by 7817.99% to -$610.0 million in 2022, then skyrocketed by 273.7% to $1.1 billion in 2023, then tumbled by 35.82% to $680.0 million in 2024, then tumbled by 68.5% to $214.2 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's EBIAT are $214.2 million (Q4 2025), $288.2 million (Q3 2025), and $30.2 million (Q2 2025).